ArticleCureus2026
Recognizing the Elephant in the Room: High Arrhythmia Risk in Hemodialysis Patients' Prescriptions.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) patients on maintenance hemodialysis are at substantial risk of developing cardiovascular events, such as torsades de pointes and sudden cardiac death. QT-prolonging drugs have been well known, but the effect of these drugs on vulnerable populations, such as hemodialysis patients, has been understudied. This study aimed to analyse the prescription pattern for arrhythmogenic drugs in CKD patients on hemodialysis and evaluate for QT prolongation.
methodsThe cross-sectional observational study was carried out in a tertiary care teaching hospital between November 2023 and March 2024 on CKD patients on maintenance hemodialysis for over three months. The demographic profile and biochemical investigations were recorded. An echocardiogram was performed to look for structural and functional abnormalities. An electrocardiogram (ECG) was obtained, and the QTc interval was calculated using the Fridericia formula. QTc prolongation was defined as > 440 ms in males and > 460 ms in females. QT-prolonging drugs were categorized using the CredibleMeds® classification into "known," "possible," and "conditional" risk groups.
resultsFifty CKD patients were studied, out of which polypharmacy was seen in 98% of prescriptions with a median of nine medications per prescription (interquartile range (IQR): 8-11), and 92% of patients were taking at least one QT-prolonging medication per prescription. Prolonged QT interval was seen in 42% of the patients. Diuretics and proton pump inhibitors were the most prescribed QT-prolonging medications.
conclusionPrescription of QT-prolonging medications is widely prevalent in hemodialysis patients, with a substantial number of them developing QT prolongation. These findings underscore the need for cautious prescribing practices in hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.